ATS Medical halves staff to cut costs
This article was originally published in Clinica
Mechanical heart valve manufacturer ATS Medical is implementing cost reduction measures - for the second time in less than a year - as it battles against strong competition. The move will see half of the workforce leave, including all executive officers apart from CEO Richard Kramp, who will remain until a new CEO can be found.
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.